The NSP4 T492I mutation increases SARS-CoV-2 infectivity by altering non-structural protein cleavage

Cell Host Microbe. 2023 Jul 12;31(7):1170-1184.e7. doi: 10.1016/j.chom.2023.06.002. Epub 2023 Jul 3.

Abstract

The historically dominant SARS-CoV-2 Delta variant and the currently dominant Omicron variants carry a T492I substitution within the non-structural protein 4 (NSP4). Based on in silico analyses, we hypothesized that the T492I mutation increases viral transmissibility and adaptability, which we confirmed with competition experiments in hamster and human airway tissue culture models. Furthermore, we showed that the T492I mutation increases the replication capacity and infectiveness of the virus and improves its ability to evade host immune responses. Mechanistically, the T492I mutation increases the cleavage efficiency of the viral main protease NSP5 by enhancing enzyme-substrate binding, which increases production of nearly all non-structural proteins processed by NSP5. Importantly, the T492I mutation suppresses viral-RNA-associated chemokine production in monocytic macrophages, which may contribute to the attenuated pathogenicity of Omicron variants. Our results highlight the importance of NSP4 adaptation in the evolutionary dynamics of SARS-CoV-2.

Keywords: NSP4; T492I; attenuated pathogenicity; immune evasion; replication.

MeSH terms

  • Animals
  • Biological Evolution
  • COVID-19*
  • Cricetinae
  • Humans
  • Mutation
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus

Substances

  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants